Director, See Remarks · Opus Genetics, Inc. · Common Stock
Side
SELL
Value
$8.60M
Shares
4.00M
Price
$2.15
Executed
Dec 9, 2025
Disclosed
Dec 11, 2025
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Dec 9 executedDec 11, 2025 disclosed
IRD · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Foundation Fighting Blindness Retinal Degeneration Fund
Role
Director, See Remarks
Transaction
Open-market saleAs filed: “S”
Asset
Opus Genetics, Inc.
Ticker
IRD
Shares
4.00M
Price per share
$2.15
Value
$8,600,000
Execution date (reported)
Dec 9, 2025
Owned after transaction
5.49M shares
Days from execution to publication
2
Calculation
Value = shares × reported price per share
Shares: 4.00M
Price: $2.15
= $8,600,000
What this establishes
Foundation Fighting Blindness Retinal Degeneration Fund filed this Form 4 reporting a open-market sale of IRD on Dec 9, 2025. It became public on Dec 11, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, See Remarks
Foundation Fighting Blindness Retinal Degeneration Fundcik:0002042266
Issuer
Opus Genetics, Inc.cik:0001228627
Revision history · 0
No field has changed since this record was first ingested.
